Fierce Pharma January 7, 2024
Eric Sagonowsky

Less than six months after Ligand Pharmaceuticals swooped in to buy Novan’s assets following the latter company’s bankruptcy, the purchase has paid off with an FDA approval.

Late Friday, the FDA approved Ligand’s Zelsuvmi for the treatment of molluscum contagiosum in patients ages 1 and older. With the nod, Ligand’s topical gel becomes the first treatment for the highly contagious viral skin infection.

Zelsuvmi can be applied by patients, parents or others at home to treat a condition that’s marked by lesions on a the skin.

The FDA approved the drug based on a pair of phase 3 studies that enrolled a total of 1,598 patients. In the B-SIMPLE 2 and B-SIMPLE4 studies, the drug showed an ability...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
MHE Week in Review – New PBM Reform Bill, Cardiac Diseases Cost
Deep learning uncovers gene targets and potential drugs to slow brain aging
FDA issues flu vaccine recommendations: 5 respiratory updates
CZI’s Priscilla Chan on ‘Virtual Cells’ AI Models to Cure Diseases
HIMSSCast: The 'genetic revolution' is underway

Share This Article